Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases

Tomohiro Sase; Hideo Wada; Yuko Kamikura; Toshihiro Kaneko; Yasunori Abe; Junji Nishioka; Tsutomu Nobori; Hiroshi Shiku

doi:10.1160/TH03-08-0535

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2004; 92(01): 132-139
DOI: 10.1160/TH03-08-0535

Platelets and Blood Cells

Schattauer GmbH

Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases

Tomohiro Sase

¹Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan

,

Hideo Wada

²Department of Laboratory Medicine, Mie University School of Medicine, Tsu, Japan

,

Yuko Kamikura

¹Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan

,

Toshihiro Kaneko

³Department of Safety Management, Mie University School of Medicine, Tsu, Japan

,

Yasunori Abe

⁴Clinical Laboratories, Mie University Hospital, Tsu, Japan

,

Junji Nishioka

⁴Clinical Laboratories, Mie University Hospital, Tsu, Japan

,

Tsutomu Nobori

²Department of Laboratory Medicine, Mie University School of Medicine, Tsu, Japan

,

Hiroshi Shiku

¹Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan

› Institutsangaben

Abstract

Summary

We compared the levels of tissue factor (TF) mRNA in leukocytes with plasma TF antigens of patients in hypercoagulable state caused by various diseases. Flow cytometric analysis showed absence of TF antigen expression on neutrophils and monocytes in healthy subjects but strong expression in both cell types of patients with infections. TF mRNA levels in leukocytes were low in healthy subjects but they were significantly elevated in patients with underlying diseases of disseminated intravascular coagulation (DIC), especially in acute myeloid leukaemia (AML) and infections. TF mRNA levels in leukocytes were significantly high in patients with all diseases except those with thrombosis, and plasma TF antigen levels were significantly high in all diseases. TF mRNA in leukocytes and plasma TF antigen levels were significantly high in patients with overt-DIC, and TF mRNA/antigen ratio was significantly high in patients with overt-DIC. In patients with solid cancers, TF mRNA and TF mRNA/antigen ratio were significantly higher in patients with metastases than those without. TF mRNA levels in leukocytes and plasma levels of TF antigen did not correlate in normal subjects and all patients, but they tended to be correlated in patients with AML, infections or overt-DIC. Our analysis suggests that TF expression in leukocytes plays an important role in various diseases but the expression level does not always correlate with plasma levels of TF antigen.

Keywords

Tissue factor - disseminated intravascular coagulation - infection - cancer - hypercoagulability

Volltext

Referenzen

References
1 Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
2 Taylor Jr. FB, Chang A, Ruf W. et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-34.
3 De Jonge E, Dekkers PE, Creasey AA. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. J Infect Dis 2001; 183: 1815-8.
4 Jilma B, Marsik C, Mayr F. et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002; 72: 403-10.
5 Contrino J, Hair G, Kreutzer DL. et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 02: 209-15.
6 Muller M, Albrecht S, Golfert F. et al. Localization of tissue factor in actin-filamentrich membrane areas of epithelial cells. Exp Cell Res 1999; 248: 136-47.
7 Masuda M, Nakamura S, Murakami T. et al. Association of tissue factor with a γ-chain homodimer of IgE receptor type I in cultured human monocytes. Eur J Immunol 1996; 26: 2529-32.
8 Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-72.
9 Franco RF, de Jonge E, Dekkers PE. et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 2000; 96: 554-9.
10 Crossman DC, Carr DP, Tuddenham EGD. et al. The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem 1990; 265: 9782-7.
11 Bevilacqua MP, Pober JS, Majeau GR. et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-7.
12 Koyama T, Nishida K, Ohdama S. et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 87: 343-7.
13 Wada H, Nakase T, Nakaya R. et al. Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation. Am J Hematol 1994; 45: 232-6.
14 Kakkar AK, DeRuvo N, Chinswangwatanakul V. et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. The Lancet 1995; 346: 1004-5.
15 Sase T, Wada H, Nishioka J. et al. Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases. Thromb Haemost 2003; 89: 660-5.
16 Taylor Jr. F, Toh CH, Hoots K. et al. Towards definition clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost 2001; 86: 1327-30.
17 Holmes VA, Wallace JMW, Gilmore WS. et al. Tissue factor expression on monocyte subpopulations during normal pregnancy. Thromb Haemost 2002; 87: 953-8.
18 Mensink E, van de Locht, Schattenberg A. et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukemia patients using realtime quantitative RT-PCR. Br J Hematol 1998; 102: 768-74.
19 Todoroki H, Nakamura S, Higure A. et al. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000; 127: 209-16.
20 Imamura T, Kaneda H, Nakamura S. New functions of neutrophils in the arthus reaction: Expression of tissue factor, the clotting initiator, and fibrinolysis by elastase. Lab Invest 2002; 82: 1287-95.
21 Giesen PL, Rauch U, Bohrmann B. et al. Bloodborn tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
22 Wada H, Nagano T, Tomeoku M. et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res 1982; 30: 315-22.
23 Amirkhosravi A, Alexander M, May K. et al. The importance of platelets in the expression of monocyte tissue factor antigen measured by new whole blood flow cytometric assay. Thromb Haemost 1996; 75: 87-95.
24 Song SJ, Wang LL, Wei WN. Tissue factor expression in human umbilical vein endothelial cells stimulated by TNF-alpha and its molecular mechanism. Zhogguo Shi Yan Xue Ye Xue Za Zhi 2003; 11: 124-7.
25 Wada H, Ohiwa M, Kaneko T. et al. Plasma level of tumor necrosis factor in disseminated intravascular coagulation. Am J Hematol 1991; 37: 147-51.
26 Wada H, Tamaki S, Tanigawa M. et al. Plasma level of IL-1β in disseminated intravascular coagulation. Thromb Haemost 1991; 65: 364-8.
27 Wada H, Tanigawa M, Wakita Y. et al. Increased plasma level of interleukin-6 in disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1993; 04: 583-90.
28 Salgado A, Boveda J, Monaterio J. et al. Inflammatory mediators and their influence on hemostasis. Haemostasis 1994; 24: 132-8.
29 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 09: 2752-5.
30 Wen ZB, Xiong SL, He XF. et al. Observation on tissue factor pathway and other coagulation parameter during the onset of acute cerebrocardiac thrombotic diseases. Thromb Res 2002; 107: 223-8.
31 Asakura H, Kamikubo Y, Goto A. et al. Role of tissue factor in disseminated intravascular coagulation. Thromb Res 1995; 80: 217-24.
32 Nakamura S. Tissue factor: Its new aspect and highly sensitive ELISA for clinical use. Hematol Oncol 1995; 31: 66-74.
33 Bogdanov VY, Balasubramanian V, Hathcock J. et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 04: 458-62.
34 Giesen PL, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-84.
35 Dasmahapatra KS, Cheung NK, Spillert C. et al. An assessment of monocyte procoagulant activity in patients with solid tumors. J Surg Res 1987; 43: 158-63.
36 Osterud B, Due Jr J. Blood coagulation in patients with benign and malignant tumors before and after surgery. Special reference to thromboplastin generation in monocytes. Scand J Haematol 1984; 32: 258-64.
37 Nakasaki T, Wada H, Shigemori C. et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002; 69: 247-54.
38 Shigemori C, Wada H, Matsumoto K. et al. Tissue factor expression and metastatic potential of colorectal cancer. Thrombo Haemost 1998; 80: 894-8.
39 Mueller BM, Reisfeld RA, Edginton TS. et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-6.